Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Phase 1 Withdrawn Novartis Pharmaceuticals Pharmaceutical Research Associates · collab

Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

The purpose of this study is to evaluate the effect of various degrees of hepatic impairment on plasma pharmacokinetics (PK), safety and tolerability of TNO155. The results of this study will guide the Novartis recommendation regarding whether or not a dose adjustment may be needed when treating patients with hepatic impairment.

Timeline

Start: 2025-03-06
Primary completion: 2025-06-26
Completion: 2025-06-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BATOPROTAFIB	Small molecule	—	Oral

Indications

No indication recorded.